The Impact of Venous Invasion on the Postoperative Recurrence of pT1–3N0cM0 Gastric Cancer

Author:

Imai Yasuo1ORCID,Kurata Yoshihiro23,Ichinose Masanori2

Affiliation:

1. Department of Diagnostic Pathology, Ota Memorial Hospital, SUBARU Health Insurance Society, 455-1 Oshima, Ota City 373-8585, Gunma, Japan

2. Department of Digestive Surgery, Shioya Hospital, International University of Health and Welfare, Yaita City 329-2145, Tochigi, Japan

3. Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba City 263-8522, Chiba, Japan

Abstract

The impact of venous invasion (VI) on postoperative recurrence in pathological (p)T1–3N0 clinical (c)M0 gastric cancer (GC) remains unclear. We investigated the association of VI grade with prognosis in 94 (78 stage I and 16 stage IIA) patients. VI was graded during pathological examinations based on the number of VIs per glass slide as follows: v0, 0; v1, 1–3; v2, 4–6; and v3, ≥7. Filling-type invasion in veins with a minor axis of ≥1 mm increased VI grade by 1. Four (4.3%) patients experienced recurrence. Recurrence increased with pT (pT1, 0.0%; pT2, 11.1%; pT3, 18.8%) and VI grade (v0, 0.0%; v1, 3.7%, v2, 14.3%; and v3, 40.0%). Recurrence was significantly more frequent in pT3 than pT1 and in v2 + v3 than v0 (p = 0.006 and 0.005, respectively). Kaplan–Meier curve analyses demonstrated a significant decrease in recurrence-free survival according to pT (p = 0.0021) and VI grade (p < 0.0001). Multivariate Cox analysis revealed a significant association of VI grade with recurrence (p = 0.049). These results suggest that VI grade is a potential recurrence predictor for pT1–3N0cM0 GC. No recurrence can be expected in cases with pT1 or VI grade v0. Adjuvant therapy might be considered for pT3 or VI grade v2 + v3.

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Reference21 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021

2. American Cancer Society (2022, March 15). Stomach Cancer Survival Rates. Available online: https://www.cancer.org/cancer/stomach-cancer/detection-diagnosis-staging/survival-rates.html.

3. National Comprehensive Cancer Network® (2022, July 23). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), fiGastric Cancer, Version 1.2021. 9 February 2021. Available online: http://www.amoydxmed.com/uploadfile/2021/0421/20210421041509309.pdf.

4. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine;Sakuramoto;N. Engl. J. Med.,2007

5. Brierley, J.D., Gospodarowicz, M.K., and Wittekind, C. (2017). TNM Classification of Malignant Tumours, Wiley Blackwell. [8th ed.].

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3